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Summary Collagen breakdown, and thus bone resorption, can now be assessed by measuring the urinary
excretion of the collagen crosslinks, pyridinoline (Pyd) and deoxypyridinoline (Dpd). In a pilot study we
measured Pyd and Dpd in 20 patients with breast cancer, ten with known bone metastases and ten with no
recognised metastases in bone or elsewhere after 1 year's subsequent follow up. Eight out of the ten patients
with metastases had crosslink excretion values higher than the reference interval, but so did some patients
without known metastatic disease. For both crosslinks there was a clear correlation with serum alkaline
phosphatase activity measured at about the same time. We consider that measurement of urinary collagen
crosslink assays may have a place in the early detection of metastatic spread to bone.
Until recently the biochemical assessment of bone resorption
has been limited by the lack of specificity of the methods
available. Urinary hydroxyproline has been widely used.
While greatly raised values are found in patients with a very
high bone turnover such as Paget's disease, hydroxyproline
assays have been less useful in demonstrating smaller changes
in bone turnover, for example, in osteoporosis or primary
hyperparathyroidism (Kivirikko, 1970; Stepan et al., 1989;
Deacon et al., 1987). The clinical usefulness of hydroxypro-
line is further limited by its derivation from tissues other
than bone and from processes other than mature collagen
turnover (Krane et al., 1977; Robins, 1982a); it is also limited
by the need for dietary restrictions to obtain the most repro-
ducible results.
In the assessment of patients with breast malignancy, the
place of hydroxyproline excretion has been explored; high
values are seen in some patients with known bone metastases
but many have values indistinguishable from normal (Roberts
et al., 1975; Cuschieri, 1977; Frenay et al., 1988). The assay
has proved to be of only limited value in the screening of
patients in the follow up clinics.
Following the identification of collagen crosslink compon-
ents in urine (Gunja-Smith & Boucek, 1981) an alternative
method for assessing collagen breakdown was developed by
using an immunoassay for pyridinoline (Robins, 1982b). Pyri-
dinoline (Pyd) is a derivative of 3-hydroxyproline (Fujimoto
et al., 1978; Robins, 1983) and is present only in extracellular
collagen fibrils. It is the principal crosslink of cartilage colla-
gen and to a smaller extent of bone collagen; it is not found
in skin collagen. High values of urinary Pyd have been
demonstrated in patients with rheumatoid arthritis and osteo-
arthritis (Robins et al., 1986; Seibel et al., 1989).
An analogous crosslink, deoxypyridinoline (Dpd) has been
identified in urine (Ogawa et al., 1982); this component is
derived almost exclusively from bone collagen (Eyre et al.,
1984). Recent work has shown that assays of Pyd and Dpd
may be valuable markers of bone resorption in a wide range
of metabolic bone diseases including Paget's disease, primary
hyperparathyroidism, osteomalacia and even osteoporosis
(Uebelhart et al., 1990; Robins et al., 1991).
We considered that the new assays might have a role in the
assessment of patients with a history of breast carcinoma to
provide early warning of bone metastases. We therefore car-
ried out a pilot study of patients with previously recognised
metastatic spread to bone and compared the results with
those from a group of patients with no known metastases
and who had been followed subsequently for not less than 1
year without evidence of metastatic disease in bone or else-
where.
Patients and methods
All the patients were surveyed at the time the samples were
obtained with a limited skeletal survey, including a chest
X-ray, and with 'mTc-polyphosphate scintigraphy. The ten
patients with known metastatic disease in bone included two
with metastatic disease also in the lungs and one who had a
lesion thought to be metastatic in the contralateral breast.
None of the patients had sclerotic metastases. At the end of
the 1 year follow-up period, the patients without metastases
were examined clinically and biochemically but the isotope
scintigraphy was not repeated at this stage.
Urine samples were frozen within 6 h of collection and
stored at -20'C. In an earlier study we had demonstrated
that repeat assays on samples stored at -20°C showed no
deterioration of the crosslinks (Robins et al., 1991). The
samples from the patients with and without metastatic spread
were treated identically and the assays were carried out with-
out knowledge of the diagnosis.
Analyses of the crosslinks were performed by HPLC
(Black et al., 1988; Seibel et al., 1989). In all cases the urine
samples (250 gil) were hydrolysed with an equal volume of
concentrated HCI to release bound forms of the crosslinks.
The results were expressed relative to the urinary creatinine
concentration. Creatinine, calcium and alkaline phosphatase
assays were done with standard automated procedures.
Statistical analyses were carried out using Student's t-test
and linear regression with Pearson's correlation coefficients.
Results
Figure 1 shows the urinary concentrations of Pyd and Dpd
relative to creatinine in the two groups of patients. Values for
a group of 118 healthy volunteers aged 21 to 74 (Seibel et al.,
1989) are shown for comparison. There were clear differences
between the two groups of patients; for Pyd/Cr, the mean
value (± s.d.) for the group with metastases (102.3 ± 67.1)
was significantly higher (P<0.025) than that for the group
without metastases (44.5 ± 17.2). The corresponding values
for Dpd (with metastases, 24.2 + 17.4; without metastases,
12.3 ± 7.4) were statistically not significantly different. The
values for the patients without known metastases were, how-
ever, significantly higher than those for the controls, with
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Figure 1 Urinary excretion of Pyd and Dpd (relative to crea-
tinine) in patients with and without known metastatic disease in
bone.
four patients having levels outside the reference interval (two
standard deviations).
At the time the urinary samples were obtained all the
patients had normal values for serum total calcium. How-
ever, four of the patients with metastatic spread and one of
those without had raised serum activity of alkaline phos-
phatase. Figure 2 shows the relationship of serum alkaline
phosphatase with urinary Pyd and with urinary Dpd.
Discussion
The assays in our small study were carried out blind but
demonstrated that many of the patients known to have bone
metastases had raised values for urinary Pyd and Dpd.
Rather surprisingly Pyd assays appeared to discriminate
better than Dpd assays between the two groups of patients
although the greater range of values for Dpd in the group
Figure 2 Urinary excretion of Pyd and Dpd (relative to crea-
tinine) compared with serum alkaline phosphatase activities. For
the whole group the correlation coefficient was 0.86 (P<0.001)
for Pyd and 0.77 (P<0.001) for Dpd. For the patients without
metastases the correlation coefficients were 0.72 (P<0.05) for
Pyd and 0.78 (P<0.02) for Dpd. The adult reference range for
serum alkaline phosphatase is 20-120 IU.
without metastases must have contributed to this finding. It
was, however, noted that some patients not thought to have
metastatic disease at the time also had raised values of Pyd
and Dpd excretion relative to our control group. Further
long-term follow up is needed to determine whether these
represent 'false positive' results or signify occult bony metas-
tases. One possible explanation would be that this finding
indicates generalised bone resorption in both patient groups,
perhaps caused by a tumour-derived cytokine or prostaglan-
din component; tumour necrosis factors and PG-E2 have
been shown to increase bone resorption in vitro (Bertolini et
al., 1986; Garrett et al., 1987). The excretion of Pyd and Dpd
was correlated with the serum alkaline phosphatase activity
suggesting that osteoblastic activity and osteoclastic activity
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increased together. However the serum assays carried out at
the time did not include y-glutamyl transferase or 5'-nucleo-
tidase so that we cannot be confident that all the alkaline
phosphatase was derived from bone. Again, further work
with larger numbers would be worthwhile.
We conclude that assays of the urinary excretion of Pyd
and Dpd could provide a valuable additional indicator of
metastatic spread to bone. We feel that further studies with
larger numbers and additional information on follow up are
needed.
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